FDA Approves Xopenex Metered-Dose Inhaler

Marlborough, Mass.

The Food and Drug Administration has approved Sepracor's drug application for an inhaler version of Xopenex. The inhalation solution is currently available for use in a nebulizer to treat respiratory disorders such as asthma and chronic obstructive pulmonary disease. Sepracor plans to launch the metered-dose inhaler version, Xopenex HFA, around the end of the year.